| Cytoreduction therapy group (n = 25) | No cytoreduction therapy group (n = 25) | P value | |
|---|---|---|---|
| Age, years median (IQR) | 75(67–78) | 65(40–71) | <0.01 |
| Sex (Female: Male) | 8:17 | 14:11 | 0.15 |
| JAK2 V617F mutation, n(%) | 11/22(50%) | 12/23(52%) | 1.0 |
| WBCs, /μL median(IQR) | 6300(5400–7700) | 9000(7600–10400) | <0.01 |
| Platelets, ×103/μL median(IQR) | 582(482–736) | 884(727–1107) | <0.01 |
| VWF:Ag, % median(IQR) | 117.7(104.1–149.0) | 94.0(53.5–111.3) | <0.01 |
| HMW‐VWFMs index, % median(IQR) | 66.5(49.0–80.0) | 48.4(32.3–55.1) | <0.01 |
| VWF‐DP/Ag ratio, median(IQR) | 1.14(0.91–1.89) | 2.16(1.90–3.15) | <0.01 |
| ADAMTS13 activity, % median(IQR) | 53.3(42.2–68.4) | 65.3(48.7–81.4) | 0.09 |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.